The Health Impact Fund: making the case for engagement with pharmaceutical laboratories in Brazil, Russia, India, and China

Abstract Despite progress in global health, the general disease burden still disproportionately falls on low- and middle-income countries. The health needs of these countries' populations are unmet because there is a shortage in drug research and development, as well as a lack of access to esse...

Full description

Saved in:
Bibliographic Details
Main Authors: Vivian Chia-Jou Lee (Author), Jacqueline Yao (Author), William Zhang (Author)
Format: Book
Published: BMC, 2021-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d648b4a07f4642afb0d13a977e29b3c5
042 |a dc 
100 1 0 |a Vivian Chia-Jou Lee  |e author 
700 1 0 |a Jacqueline Yao  |e author 
700 1 0 |a William Zhang  |e author 
245 0 0 |a The Health Impact Fund: making the case for engagement with pharmaceutical laboratories in Brazil, Russia, India, and China 
260 |b BMC,   |c 2021-09-01T00:00:00Z. 
500 |a 10.1186/s12992-021-00744-x 
500 |a 1744-8603 
520 |a Abstract Despite progress in global health, the general disease burden still disproportionately falls on low- and middle-income countries. The health needs of these countries' populations are unmet because there is a shortage in drug research and development, as well as a lack of access to essential drugs. This health disparity is especially problematic for diseases associated with poverty, namely neglected tropical diseases and microbial infections. Currently, the pharmaceutical landscape focuses on innovations determined by profit margins and intellectual property protection. To expand drug accessibility and catalyze research and development for neglected diseases, a team of researchers proposed the Health Impact Fund as a potential solution. However, the fund is predominantly considering partnerships with pharmaceutical giants in high-income countries. This commentary explores the limitations and benefits in partnering with pharmaceutical companies based in Brazil, Russia, India, and China (BRIC), with the goal of expanding the Health Impact Fund's vision to incorporate long-term, local partnerships. Identified limitations to a BRIC country partnership include lower levels of drug development expertise compared to their high-income pharmaceutical counterparts, and whether the Health Impact Fund and the participating stakeholders have the financial capability to assist in bringing a new drug to market. However, potential benefits include the creation of new incentives to fuel competitive local innovation, more equitable routes to drug discovery and development, and a product pipeline that could involve stakeholders in lower- and middle-income countries. Our commentary explores how partnership with pharmaceutical firms in BRIC countries might be advantageous for all: The Health Impact Fund, pharmaceutical companies in BRIC economies, and stakeholders in low- and middle- income countries. 
546 |a EN 
690 |a Pharmaceutical innovation 
690 |a R&D 
690 |a drug development 
690 |a LMIC 
690 |a BRIC 
690 |a Health Impact Fund 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Globalization and Health, Vol 17, Iss 1, Pp 1-7 (2021) 
787 0 |n https://doi.org/10.1186/s12992-021-00744-x 
787 0 |n https://doaj.org/toc/1744-8603 
856 4 1 |u https://doaj.org/article/d648b4a07f4642afb0d13a977e29b3c5  |z Connect to this object online.